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A B S T R A C T
Purpose: The purpose of the study was to determine the frequency of occurrence of polymorphisms of
genes MTHFR (C677T), MTR (A2756G), and MTHFD1 (G1958A), as well as to analyze the concentration of
homocysteine (Hcy), methionine (Met), asymmetric dimethylarginine (ADMA), and arginine (Arg) in
epileptics treatment with antiepileptic drugs (AEDs), and controls.
Method: The study included 65 epileptic patients treated with variable AEDs and 61 controls. The levels
of Hcy and Met were determined by HPLC/EC, ADMA and Arg by HPLC with ﬂuorescence detection.
Polymorphisms of the studied genes were determined by PCR-RFLP.
Results: The study demonstrates that AEDs treatment in epileptics leads to increase in Hcy (p < 0.05) and
ADMA (p < 0.01) concentrations. Greater increases in Hcy concentration during AEDs treatment appear
to occur in individuals with the MTHFR CT (C677T) and MTHFD1 GG (G1958A) genotypes. Genetic
conditions also appear to be related with changes in the ratios of Hcy, Met, Arg, and ADMA. It seems that
in cases of AEDs treatment’s effect on hyperhomocysteinemia, epileptic individuals appear to have a
disturbed control of Hcy over ADMA.
Conclusions: It is possible, that polymorphisms of genes related to Hcy-to-Met metabolism, in epileptics
treated with AEDs may have an effect on the regulation of levels of risk factors of vascular diseases, Hcy
and ADMA.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The last decade has seen many studies on hyperhomocystei-
nemia (HHcy) in epileptic patients treated with antiepileptic drugs
(AEDs). It has been shown that HHcy occurs in 10–40% of the
epileptic population,1,2 and that AEDs pharmacotherapy has a
fundamental effect on the levels of homocysteine (Hcy) in both
children3–5 and adults.6–9
Furthermore, it has been demonstrated that a speciﬁc
predisposition to generate circulating Hcy in patients with gene
polymorphisms in both the cystathionine beta-synthase (CBS) and
methylenetetrahydrofolate reductase (MTHFR) C677T2,7 and
A1298C10,11 genes is an important factor in the levels of HHcy
in epileptics treated with AEDs. The study by Mudd et al.12 shows
that 20% of the heterozygote CBS patients have epileptic seizures
when circulating Hcy increases from 50 to 200 mM. It has also been* Corresponding author. Tel.: +48 061 86 91 439; fax: +48 061 86 91 697.
E-mail address: dorszewskaj@yahoo.com (J. Dorszewska).
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doi:10.1016/j.seizure.2011.04.001shown that, in women with generalized idiopathic epilepsy, the
frequency of the MTHFR TT (C677T) homozygote is increased, with
this polymorphism also possibly increasing the risk of becoming an
epileptic.13 Moreover, it has been demonstrated that both
heterozygote and homozygote individuals with the MTHFR
(C677T) polymorphism have a signiﬁcantly increased level of
Hcy and decreased levels of folates (FA), especially in polytherapy
with AEDs.7,14,15
The literature indicates that Hcy formation in epileptics treated
with AEDs may also involve 5,10-methylenetetrahydrofolate
reductase (MTR). Studies on animal models have shown that
phenytoin administration can both decrease16 and increase17 MTR
activity.
It is also known that the three-functional enzyme, methylene-
tetrahydrofolate dehydrogenase/methynyltetrahydrofolate cyclo-
hydrolase/formyltetrahydrofolate synthetaze (MTHFD1) is
involved in the regulation of circulating Hcy. It has been shown
that MTHFD1 homozygotes experience an increase in Hcy levels in
heart disease and dysgenesis of the neural tube dependent on FA
levels,18 while MTHFD1 GA (G1958A) heterozygotes with Alzhei-vier Ltd. All rights reserved.
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ratios (Cys:Hcy).19 However, there is no literature on the
contribution of MTHFD1 in the generation of Hcy in epileptics
treated with AEDs.
It is believed that an increased concentration of Hcy by
inhibition of dimethylaminohydrolase (DDAH) may lead to an
accumulation of asymmetric dimethylarginine (AMDA) and a drop
in production of nitric oxide (NO).20 Most studies looking at
patients with vascular disease conﬁrm an increase in ADMA in
HHcy,21–24 but there are also indications of a disturbed relation-
ship between Hcy and ADMA in HHcy.25,26 However, there is a lack
of information on the effect of AEDs on ADMA in HHcy in epileptic
patients.
It has been shown that ADMA may also participate in the
atherosclerotic function of Hcy,22 and that an increased concen-
tration of plasma ADMA in patients with atherosclerosis is
associated with the degree of vascular endothelium dysfunction
and the severity of atherosclerosis.27,28
The purpose of this study was to determine the frequency of
polymorphism incidence for the MTHFR (C677T), MTR (A2756G),
and MTHFD1 (G1958A) genes, and to analyze the levels of the
sulphur-containing amino acids Hcy and Met as well as ADMA and
Arg in epileptic patients treated with variable AEDs, and control
group. The genotypes of the genes involved in the formation of Met
from Hcy were also taken into account with regards to the
analyzed biochemical parameters in the study participants.
2. Methods
2.1. Patients
The studies were conducted on 65 patients with epilepsy,
treated with variable AEDs (Table 1).
In the group of patients treated with AEDs, the mean levels of
VPA and CBZ were within the reference values and averaged
56.5 mg/ml and 5.8 mg/ml, respectively.
The classiﬁcation of epilepsy and/or epileptic syndrome
suffered by each patient was veriﬁed according to the criteria
and terminology recommended by the Commission on Classiﬁca-
tion and Terminology of The International League Against
Epilepsy.29
The control group included 61 individuals, 41 women and 20
men, aged 22–67 years (mean age: 44.3  14.2 years).
None of the epileptic patients and control subjects (epileptic
patients and controls – Caucasian), were diagnosed with impaired
liver or kidney function or smoking and drinking habits. None of
the patients and controls had been receiving B group vitamin or FA
supplementation. Moreover, epileptic patients, a few hours before
testing took their AEDs dose.
None of the control subjects had veriﬁable symptoms of
dementia or any other neurological disorders.
A Local Ethical Committee approved the study and the written
consent of all patients or their caregivers was obtained.Table 1
Characteristics of 65 epileptic patients treated with different AEDs.
Patients, n (%)
Age: aged/mean age 18–70/37.3  13.6 years
Sex: male/female 36 (55%)/29 (45%)
Type of epilepsy
Cryptogenic 65 (100%)
Antiepileptic drugs
Monotherapy 44 (68%)
Polytherapy 21 (32%)
n: Number of patients.2.2. Analysis of Hcy and Met concentrations
2.2.1. Preparation of samples
The analyzed plasma thiol compounds (Hcy, Fluka Germany;
Met, Sigma, USA) were diluted with water at a 2:1 ratio and
reduced using 1% TCEP (Tris-(2-carboxyethyl)-phosphin-hydro-
chloride; Applichem, Germany) at a 1:9 ratio. Subsequently, the
sample was deproteinized using 1 M HClO4 (at a 2:1 ratio) and
applied to the HPLC/EC system.
2.2.2. Determination of thiol concentration
The samples were fed to the HPLC system (P580A; Dionex,
Germany) coupled to an electrochemical detector (CoulArray
5600; ESA, USA). The analysis was performed in Termo Hypersil
BDS C18 column (250 mm  4.6 mm  5 mm) (Germany)
in isocratic conditions, using the mobile phase of 0.15 M
phosphate buffer, pH 2.9, supplemented with 12.5–17% aceto-
nitrile for estimation of Hcy and Met and 0.15 M phosphate
buffer.30
The system was controlled and the data were collected and
processed using Chromeleon software (Dionex, Germany).
2.3. Estimation of ADMA and Arg levels
2.3.1. Preparation of samples and derivatization
Plasma and the standard, containing a solution of Arg and
ADMA (Sigma, USA), were diluted with water at a ratio of 1.5:1.0
and, were then deproteinized using 8 M HCLO4 at a ratio of 5:1.
Directly before HPLC analysis, the samples were subjected to
derivatization in a solution containing 10 mg OPA per 100 ml
methanol supplemented with 900 ml 0.4 M borate buffer (pH 8.5)
and 5 ml 2-mercaptoethanol at a ratio of 1:1.31
2.3.2. Analysis of ADMA
The samples were fed to the HPLC system (P580A; Dionex,
Germany) coupled to a ﬂuorescence detector (RF2000; Dionex,
Germany). The analysis was performed in a Termo Hypersil BDS
C18 column (250 mm  4.6 mm  5 mm) (Germany) in isocratic
conditions using 0.1 M phosphate buffer, pH 6.75, with 25%
methanol as the mobile phase. Arg and its methylated metabolites
were measured ﬂuorometrically at excitation and emission
wavelengths of 340 nm and 455 nm, respectively.
The system was controlled and the data were collected and
processed using Chromeleon software (Dionex, Germany).
2.4. Genotyping by RFLP
Genotyping for polymorphisms in MTHFR (C677T), MTR
(A2756G) and MTHFD1 (G1958A) was conducted using PCR–RFLP
technique. PCR products were generated by using 10 ng of
genomic DNA in 25 ml of the reaction mixture containing
20 mM Tris–HCl, 50 mM KCl, 1.5 mM MgCl2, 0.11 mM each dNTP,
0.3 mM of each primer (Table 2) and 1 U Taq DNA polymerase
(Sigma–Aldrich, USA). The PCR products were digested with an
appropriate restriction endonuclease (Fermentas, Vilnius, Lithua-
nia), which recognizes and cuts either wild-type or variant
sequence, at 37 8C for at least 3 h. The digested fragments were
resolved on a 2% agarose gel, in 0.5  TBE buffer, and were stained
with ethidium bromide for visualization under UV light. The
results were conﬁrmed by direct sequencing of the ampliﬁed
fragments.
2.5. Statistical analysis of results
The obtained results were analyzed using the nonparametric
Mann–Whitney’s test and nonparametric Kruskal–Wallis test.
Table 2
Primers and restriction enzymes used for genotyping various polymorphisms in patients with epilepsy and the control group.
Gene Polymorphism Restriction enzyme Primers Annealing temp. (8C) Fragment size (bp)
Type Sequence, 50–30
MTHFR C677T HinfI Sense AGG CTG TGC TGT GCT GTT G 66 477
Antisense CGC TGT GCA AGT TCT GGA C
MTR A2756G HaeIII Sense GTT GGT GAA GGG AGA AGA AAT G 56 583
Antisense CTG AAG AAT GGG GGT CTG TG
MTHFD1 G1958A MspI Sense TTC TTC TCA TTC TTC CTC ACA CC 60 416
Antisense TCT GCT CCA AAT CCT GCT TC
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The frequency of the MTHFR (C677T), MTR (A2756G) and
MTHFD1 (G1958A) gene polymorphisms was studied, as were the
levels of plasma Hcy and Met as well as ADMA and Arg of epileptic
patients treated by variable AEDs, and the control group.
The study revealed that the epileptics treated with various AEDs
have a signiﬁcant increased in their plasma concentration of Hcy
(Mann–Whitney test, p < 0.05 compared to controls) (Table 3). It
was also shown that an increase in Hcy concentration above the
minimum required to diagnose mild HHcy (above 16 mM)
occurred in 28% of the patients, while an increase above the
normal range (above 15 mM) occurred in 35% of epileptics treated
with AEDs. Simultaneously, the concentration of Met was
signiﬁcantly decreased in epileptics treatment with AEDs, together
with a decreased Met:Hcy ratio (Mann–Whitney test, p < 0.001
compared to controls). Moreover, epileptics treated with AEDsFig. 1. Concentrations of ADMA and Arg in 47 epileptic patients with Hcy belo
Table 3
Concentrations of Hcy, Met, ADMA, and Arg in 65 epileptic patients treated with
different AEDs, and 61 controls.
Analyzed compound Control group Epileptic patients p
Hcy [mM] 11.9  4.0 14.4  6.8* 0.0141
Met [mM] 22.6  6.0 19.0  8.0*** 0.0002
Met:Hcy 2.1  0.9 1.5  0.8*** 0.0001
ADMA [mM] 1.6  1.0 2.3  1.3** 0.0049
Arg [mM] 73.7  25.7 66.0  29.3* 0.0337
Arg:ADMA 85.7  120.7 41.0  36.0*** 0.0001
Results are presented as mean  SD.
Non-parametric Mann–Whitney test for independent variables was used.
* Statistically signiﬁcant difference at p < 0.05 compared to controls.
** Statistically signiﬁcant difference at p < 0.01 compared to controls.
*** Statistically signiﬁcant difference at p < 0.001 compared to controls.demonstrated an increase in concentration of ADMA (Mann–
Whitney test, p < 0.01 compared to controls), while the Arg
concentration (Mann–Whitney test, p < 0.05 compared to con-
trols) and Arg:ADMA (Mann–Whitney test, p < 0.001 compared to
controls) level ware concurrently signiﬁcantly decreased.
Analysis of the biochemical parameters (ADMA, Arg) concen-
trations in AEDs-treated epileptics with mild HHcy (Hcy > 16 mM)
(Fig. 1) revealed that these patients did not have an increase in
ADMA levels (Kruskal–Wallis test, for patients with Hcy < 16 mM,
p < 0.05 compared to controls), while the concentration of
Arg:ADMA ratio (Kruskal–Wallis test, for patients with
Hcy < 16 mM, p < 0.001 compared to controls) and Arg was
slightly increased as compared to AEDs-treated epileptics with
concentrations of Hcy < 16 mM.
The frequency of the C677T polymorphism of the coding gene
MTHFR (Table 4) was also analyzed, and demonstrated a variable
distribution of genotypes of this gene both in controls and inw and 18 above 16 microM treated with different AEDs, and 61 controls.
Table 4
Frequency of the occurrence of genotypes of the MTHFR C677T, MTR A2756, and
MTHFRD1 G1958A gene polymorphisms in epileptic patients, and controls.
Gene Genotype Control group, n (%) Epileptic patients, n (%)
MTHFR CC 24 (44) 36 (55)
C677T CT 29 (52) 22 (34)
TT 2 (4) 7 (11)
MTR AA 37 (67) 36 (55)
A2756G AG 18 (33) 26 (40)
GG 0 (0) 3 (5)
MTHFD1 GG 15 (27) 14 (21)
G1958A GA 30 (54) 35 (54)
AA 10 (19) 16 (25)
n: Number of subjects.
Table 5
Concentrations of Hcy, Met, ADMA, and Arg depending on the genotypes of MTHFR C677T in epileptic patients treated with different AEDs, and controls.
Analyzed compound Control group
MTHFR C677T
Epileptic patients
MTHFR C677T
p
CC (n = 24) CT (n = 29) CC (n = 36) CT (n = 22) CC
CT
Hcy [mM] 12.4  4.6 11.1  3.7 13.5  5.1 14.0  6.6* 0.1974
0.0500
Met [mM] 23.0  6.1 22.3  4.8 20.2  9.0* 18.1  6.1** 0.0276
0.0070
Met:Hcy 2.1  1.0 2.2  0.9 1.7  0.9* 1.4  0.5** 0.0466
0.0013
ADMA [mM] 1.6  0.9 1.3  1.0 2.1  1.1 2.6  1.5** 0.0756
0.0021
Arg [mM] 74.6  26.6 66.4  22.3 71.4  32.7 54.1  23.1* 0.2684
0.0414
Arg:ADMA 75.1  68.1 124.2  177.1 44.6  32.9 34.5  43.7*** 0.0501
<0.0001
Results are presented as mean  SD, n: number of subjects.
Non-parametric Mann–Whitney test for independent variables was used.
* Statistically signiﬁcant difference at p < 0.05 compared to controls.
** Statistically signiﬁcant difference at p < 0.01 compared to controls.
*** Statistically signiﬁcant difference at p < 0.001 compared to controls.
Table 6
Concentrations of Hcy, Met, ADMA, and Arg depending on the genotypes of MTR A2756G in epileptic patients treated with different AEDs, and controls.
Analyzed compound Control group
MTR A2756G
Epileptic patients
MTR A2756G
p
AA (n = 37) AG (n = 18) AA (n = 36) AG (n = 26) AA
AG
Hcy [mM] 12.9  5.1 10.6  3.8 14.0  5.4 14.0  5.9 0.1841
0.0542
Met [mM] 22.9  6.8 21.6  4.3 18.7  7.1** 19.0  8.9* 0.0064
0.0334
Met:Hcy 2.1  1.0 2.2  1.0 1.5  0.8** 1.5  0.8* 0.0069
0.0189
ADMA [mM] 1.6  1.0 1.4  1.0 2.3  1.3* 2.4  1.3* 0.0184
0.0214
Arg [mM] 70.2  26.5 82.7  23.5 63.9  28.8 67.4  32.4* 0.1097
0.0326
Arg:ADMA 79.6  83.1 145.5  235.0 37.8  27.0** 42.4  46.9** 0.0054
0.0035
Results are presented as mean  SD, n: number of subjects.
Non-parametric Mann–Whitney test for independent variables was used.
* Statistically signiﬁcant difference at p < 0.05 compared to controls.
** Statistically signiﬁcant difference at p < 0.01 compared to controls.
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homozygous incorrect TT genotype (C677T MTHFR) was found in
the control group. The epileptic patient group demonstrated a
higher number of individuals homozygous for both the wildtype
CC genotype and the incorrect TT genotype (nearly 3-fold increase
from the control group in the case of the TT genotype) of the C677T
MTHFR polymorphism.
In the case of the MTR (A2756G) coding gene (Table 4), the
control group demonstrated the highest number of the wildtype
AA (A2756G MTR) genotype and no homozygotes for the incorrect
GG genotype (A2756G MTR). However, the patient group
contained an increasing number of AG heterozygotes (A2756G
MTR) and also had homozygotes for the incorrect GG genotype
(A2756G MTR).
For the G1958A MTHFD1 polymorphism, the patient group
contained more AA homozygotes (G1958A MTHFD1) than the
control group (Table 4), though both the control group and patient
group showed the same percent of the heterozygous GA (G1958A
MTHFD1) genotype. The wildtype homozygous GG genotype
(G1958A MTHFD1) was observed in similar numbers in bothgroups, and was higher than the number of the incorrect AA
genotype (G1958A MTHFD1) only in the control group.
The concentrations of the studied biochemical parameters (Hcy,
Met, ADMA and Arg) were also analyzed with respect to the MTHFR
(C677T) gene genotypes (Table 5). There was a signiﬁcant increase
in the concentration of Hcy (Mann–Whitney test, p < 0.05
compared to controls) and ADMA (Mann–Whitney test, p < 0.01
compared to controls) in patients treated with AEDs and having the
heterozygous MTHFR CT (C677T) genotype. In patients with the
wildtype homozygous MTHFR CC (C677T) genotype (Mann–
Whitney test, p < 0.05 compared to controls), and MTHFR CT
(C677T) genotype (Mann–Whitney test, p < 0.01 compared to
controls) there was a signiﬁcant decrease in Met concentration.
Both the patients with the wildtype homozygous, MTHFR CC
(C677T) (Mann–Whitney test, p < 0.05 compared to controls), and
with the heterozygous MTHFR CT (C677T) genotype (Mann–
Whitney test, p < 0.01 compared to controls), there was a decrease
in both the Met:Hcy ratio and the Arg:ADMA ratio (Mann–Whitney
test, in patients with MTHFR CT (C677T), p < 0.001 compared to
controls). Due to the small number of individuals having the
Table 7
Concentrations of Hcy, Met, ADMA, and Arg depending on the MTHFD1 G1958A genotypes in epileptic patients treated with different AEDs, and controls.
Analyzed compound Control group
MTHFD1 G1958A
Epileptic patients
MTHFD1 G1958A
p
GG (n = 15) GA (n = 30) AA (n = 10) GG (n = 14) GA (n = 35) AA (n = 16) GG
GA
AA
Hcy [mM] 10.1  3.4 14.4  4.4 11.6  4.9 13.3  4.8* 14.2  6.2 14.0  4.6 0.0441
0.3265
0.0812
Met [mM] 23.2  5.3 22.5  7.0 18.5  5.9 16.9  5.3* 17.2  6.3** 23.3  10.7 0.0125
0.0041
0.3398
Met:Hcy 2.6  1.0 1.7  0.8 1.8  0.7 1.4  0.6** 1.4  0.7 1.8  1.0 0.0017
0.0858
0.2907
ADMA [mM] 1.0  0.6 1.7  0.8 2.0  1.5 2.8  1.3*** 1.9  1.2 2.9  1.2 0.0006
0.4511
0.1511
Arg [mM] 67.1  19.1 75.2  21.9 76.6  40.1 57.9  25.2 62.3  25.4* 79.8  38.2 0.1568
0.0193
0.4548
Arg:ADMA 146.7  234.2 56.7  37.3 95.7  115.9 25.1  18.2*** 48.0  38.7 38.4  40.3* 0.0002
0.1603
0.0474
Results are presented as mean  SD, n: number of subjects.
Non-parametric Mann–Whitney test for independent variables was used.
* Statistically signiﬁcant difference at p < 0.05 compared to controls.
** Statistically signiﬁcant difference at p < 0.01 compared to controls.
*** Statistically signiﬁcant difference at p < 0.001 compared to controls.
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group, 7 from the patient group), this genotype was not subjected
to statistical analysis of the studied biochemical parameters.
In the case of epileptic patients treated with AEDs with either
the wildtype homozygous MTR AA (A2756G) genotype or the MTR
AG (A2756G) heterozygous genotype (Table 6), there was no
signiﬁcant increase in Hcy, although these patients demonstrated a
signiﬁcant increased in ADMA concentration (Mann–Whitney test,
p < 0.05 compared to controls). Furthermore, both in patients with
the MTR AA (A2756G) wildtype homozygous genotype (Mann–
Whitney test, p < 0.01 compared to controls) and the MTR AG
(A2756G) heterozygous genotype (Mann–Whitney test, p < 0.05
compared to controls), there was a decrease in Met concentration
and the Met:Hcy ratio, while in patients with just the MTR AG
(A2756G) heterozygous genotype there was also a decrease in Arg
concentration.
Moreover, only patients with the wildtype MTHFD1 GG
(G1958A) homozygous genotype (Table 7) and treated with AEDs
demonstrated a signiﬁcant increase in Hcy concentration (Mann–
Whitney test, p < 0.05 compared to controls) along with an
increase in ADMA concentration (Mann–Whitney test, p < 0.001
compared to controls). The concentration of Met was decreased in
both the patients with the MTHFD1 GG (G1958A) wildtype
homozygous genotype (Mann–Whitney test, p < 0.05 compared
to controls) and in those with the MTHFD1 GA (G1958)
heterozygous genotype (Mann–Whitney test, p < 0.01 compared
to controls), though the Met:Hcy ratio (Mann–Whitney test,
p < 0.01 compared to controls) and Arg:ADMA radio (Mann–
Whitney test, p < 0.001 compared to controls) was concurrently
signiﬁcantly decreased only in patients with the wildtype
homozygous genotype, MTHFD1 GG (G1958A). There was a
signiﬁcant decrease in the Arg:ADMA ratio (Mann–Whitney test,
p < 0.05 compared to controls) in the patients with the incorrect
MTHFD1 AA (G1958A) homozygous genotype, while the patients
with the MTHFD1 GA (G1958A) heterozygous genotype demon-
strated a signiﬁcant decrease in Arg concentration (Mann–
Whitney test, p < 0.05 compared to controls).It was also shown that all of the examined epileptic patients
with gene polymorphisms of those genes related to Hcy-to-Met
metabolism, MTHFR (C677T), MTR (A2756G), and MTHFD1
(G1958A), who had increased plasma concentrations of Hcy
(whether signiﬁcant and/or insigniﬁcant) had an accompanying
increase in plasma concentration of ADMA (Tables 5–7).
4. Discussion
There is much published literature demonstrating an increase
in the plasma concentration of Hcy in epileptic patients treated
with AEDs. These articles indicate that pharmacologic treatment in
epileptic patients can lead to an increase in Hcy that may be due to
various factors, including the pharmacotherapy and genetic
factors.
Furthermore, it appears that generation of Hcy in epileptic
patients is affected mainly not by the disease itself, but the
pharmacologic treatment for the disease. This is demonstrated by
studies conducted on a Greek population, in epileptic children aged
4.5–14 years treated by AEDs for 20 weeks,5 by studies conducted
on epileptic adult patients treated with AEDs in mono- and
polytherapy for over 30 days.6
The generation of Hcy in epileptic patients, as demonstrated by
the literature, is related both to AEDs [such as phenytoin,
phenobarbital, primidone, and carbamazepine (CBZ)] inducing
microsomal liver enzymes and increasing cytochrome P450
enzyme activity, which leads to a decrease in FA serum
concentration, as well as AEDs [such as valproic acid (VPA)] that
induce liver enzymes to a smaller degree and have a lesser effect on
the concentration of FA in blood serum.32 An increase in Hcy and
accompanying decrease in FA concentration in epileptic patients
after receiving CBZ was demonstrated in the studies by Verrotti
et al.,3 Karabiber et al.4 and Attilakos et al.5 In epileptics taking VPA,
an increase in Hcy concentration was demonstrated both
accompanying a decrease in FA3,4 and without FA changes.5
It is believed that a decrease in FA concentration during AEDs
treatment is due to impaired intestinal absorption of FA, an
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liver enzymes leading to a ﬁnal decrease in FA concentration, direct
interactions between FA and AEDs caused by structural similarities
between coenzymes for FA and AEDs, or a direct effect AEDs on Hcy
metabolism and kidney function.33
It is also known that insufﬁciency of the cofactors needed for
the remethylation of Hcy (vitamin B12, FA) can lead to decreased
efﬁciency of this process, which results in a decrease of Met
concentration. A decrease in Met concentration in epileptic
patients was demonstrated by Ono et al.34 as well as the present
study. This study has also shown that a decrease in the Met:Hcy
ratio accompanied the decrease of Met concentration. According to
one of the newer theories,35 a decrease in the Met:Hcy ratio may be
related to the transformation of Hcy to thiolactone in endothelium
and mediate Hcy-induced atherosclerotic changes.
Engbersen et al.36 demonstrated that there is a strong indirect
effect of the MTHFR enzyme on the effectiveness of Hcy
remethylation to Met. The point mutation C677T of the MTHFR
encoding gene is related to the above process. According to the
literature and present study, the Polish (19 and present study),
Norwegian,7 British,13 Korean,14 and Turkish37 populations have
demonstrated that the least common genotype of this gene was
the homozygous genotype MTHFR TT (C677T) and appeared to
have an increased frequency of occurrence in patients suffering
from epilepsy. It is believed that the MTHFR encoding gene
polymorphism leads to disturbances in the remethylation process
of Hcy to Met and an increase in Hcy due to a decrease in FA-
dependent enzyme activity. It is also believed that the C ! T
transition in the MTHFR (C677T) gene decreases enzyme activity
by 50%,38 while homozygous TT forms of this gene decrease its
activity by 30%.39 There are also reports in the literature that the
Korean population14 only the homozygous MTHFR TT (C677T)
genotype leads to a signiﬁcant increase of Hcy, and only in
epileptic patients treated with medications inducing liver
enzymes and decreasing FA (CBZ). In the present study, the
concentration of Hcy has signiﬁcantly increased in heterozygous
MTHFR CT (C677T) epileptic patients treated with various AEDs
both in mono- and polytherapy. Analysis of the data gives an
absolute correlation of AEDs with the MTHFR C677T polymor-
phism. The synergistic effects of AEDs inducing liver enzymes
with the heterozygous MTHFR CT (C677T) genotype are conﬁrmed
by Apeland et al.7 Though the study by Vurucu et al.37
demonstrates that the MTHFR C677T polymorphism is not
involved in HHcy in epileptic patients treated with CBZ, while
Ono et al.15 showed that this polymorphism is only involved in
HHcy in epileptic patients treated with polytherapy.
It has also been shown that the use of phenytoin may lead to
decreased MTR activity in the remethylation of Hcy to Met, which
affects the regulation of Met levels.16 It seems that in the present
study neither mono- nor polytherapy of epileptic patients with
various AEDs leads to a signiﬁcant decrease in MTR enzyme
activity.
Furthermore, the present study demonstrates that MTHFD1
(G1958A), and especially the correct homozygous MTHFD1 GG
(G1958A) genotype, is also involved in the formation of plasma Hcy
in epileptic patients treated with AEDs in mono- and/or
polytherapy.
The present study also shows that gene polymorphisms of the
studied genes involved in remethylation of Hcy to Met in epileptic
patients treated with AEDs may also contribute to disturbances in
the corresponding levels of Met and Hcy, which can therefore lead
to an increase in Hcy levels.
As demonstrated, an increase of Hcy concentration above
15 mM in epileptic patients treated with AEDs may lead to several
clinical complications. It is known that such increases can raise the
risk of myocardial infarction three-fold and the risk of carotidartery stenosis two-fold,40 and can also lead to vascular41,42 and
neuropsychiatric33 diseases, as well as increasing the risk of
epileptic seizures and AEDs resistance.43
Over the past few years, there have been several articles
emphasizing the correlation between HHcy and the concentration
of ADMA in vascular disease.22–24,44 Many of these articles indicate
an increase in serum ADMA in HHcy with coronary artery
disease,45 peripheral artery disease,46 and stroke.22 An increase
in ADMA concentration in HHcy has been explained by several
theories. One of these theorizes that formation of serum ADMA
may occur in an environment of increased Met concentration, due
to high Hcy levels in HHcy, with the participation of SAM, which
leads to an increased production of ADMA from Arg via increased
enzyme activity of SAM-dependent protein N-methyltransferase
(PRMT) or inappropriate regulation of this gene’s expression under
HHcy conditions.20,47 Another theory suggests an increase of
ADMA in HHcy resulting from decreased renal secretory function25
or decreased expression and activity of DDAH, which is known to
be responsible for breaking down ADMA to L-citrulline.48 It has
been shown that, under in vitro conditions, Hcy may directly arrest
DDAH enzyme activity through its oxidative inactivation, thereby
leading to an increase in ADMA concentration.20
Increases in ADMA concentration under conditions of increas-
ing Hcy seem to be both due to organic factors45,46 and due to
pharmacotherapy, as shown in the present study. The present
study demonstrates an increase in Hcy accompanied by an increase
in ADMA in epileptic patients receiving AEDs, regardless of the
medications used or the gene polymorphisms of genes encoding
enzymes involved in the metabolism of Hcy to Met. Furthermore,
in the studies of Jonasson et al.25 and Wanby et al.,26 during long-
term treatment with AEDs it was demonstrated that patients with
vascular disease, in HHcy, the concentration of ADMA was not
always increased. As has been demonstrated in vascular disease
patients, a lack of ADMA increase under HHcy conditions is most
likely due to a concurrent mild renal insufﬁciency in these patients
(the secretory function of the kidneys is slightly but insigniﬁcantly
increased).
Furthermore, it has been shown that ADMA may participate in
the atherosclerotic function of Hcy.22 ADMA is one of the risk
factors of circulatory system diseases,49 as well as a marker of
atherosclerosis.27,28,50,51 The pathological function of ADMA is
related both to increase in its level and to decreased concentrations
of its metabolite and substrate to NO production, Arg. The present
study indicates that a decrease in Arg levels in epileptic patients
may be due to certain genetic predispositions. Among the patient
group, MTR AG (A2756G) and MTHFD1 GA (G1958A) heterozygotes
appeared to be more predisposed to decreases in the levels of this
amino acid. It also seems that a decrease in Arg levels in epileptic
patients treated with AEDs may be related to the epileptogenetic
mechanism, in which there is a many-fold increase in Arg-utilizing
biosynthesis of neurotransmitters that have stimulatory (gluta-
mate) and inhibitory (GABA) actions,52,53 or may be due to a
mobilization of the organism to counteract the overstimulation
caused by the action of many AEDs (increase in GABA concentra-
tion). A decrease in Arg in epileptic patients also seems to have an
effect on the Arg:ADMA ratio, which according to Dayal and
Lentz54 may be due to increasing oxidative stress accompanying
increases in Hcy levels. The study by Maas55 indicates that, in
conditions of oxidative stress related to pharmacologic interven-
tion, there is ADMA generation through a change in the expression
of genes responsible for the synthesis and breakdown of ADMA.
The studies by Matsuoka et al.56 and Kielstein et al.49 demonstrate
that disturbances in the Arg:ADMA ratio may lead to hypercholes-
terolemia, arterial hypertension, and diseases of the heart and
blood vessels. Many studies have demonstrated the success of B-
group vitamins and FA supplementation in decreasing Hcy levels in
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Sydow et al.,46 conducted on HHcy patients with peripheral
vascular disease, demonstrated that B-group vitamin supplemen-
tation helps regulate only Hcy levels and does not have a sufﬁcient
effect to decrease ADMA levels. Moreover, the studies by Sydow
et al.46 and Koga et al.57 indicate that, to regulate both Hcy and
ADMA, patients require combined therapy with B-group vitamins,
FA, and Arg. The effectiveness of this combined therapy on
epileptic patients treated with AEDs appears to also be indicated by
the result analysis obtained for Met and Arg after treatment with
this therapy in the present study.
5. Conclusions
The present study demonstrates that AEDs pharmacotherapy in
epileptic patients leads to increases in Hcy and ADMA levels.
Individuals with the MTHFR CT (C677T) and MTHFD1 GG (G1958A)
genotypes seem to have greater predisposition to Hcy concentra-
tion increase during AEDs treatment. Genetic factors also appear to
be related to disturbances in Met:Hcy and Arg:ADMA ratios. Under
HHcy conditions related to AEDs treatment of epileptic patients,
the feedback control of Hcy over ADMA appears to be disturbed. It
is possible, that polymorphisms of genes related to Hcy-to-Met
metabolism, may have an effect on the regulation of levels of Hcy
and ADMA in epileptics treated with AEDs.
Our results indicate that further analysis should be
performed in epileptic patients treated with AEDs to determine
the concentration of Hcy and ADMA, as well as genotype
analysis of genes coding enzymes converting Hcy, especially
MTHFR and MTHFD1, in epileptic patients with HHcy. The
administration of L-arginine along with vitamins B6, B12, and
folates in epileptic patients may offer new therapy in the
treatment of epilepsy.
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